60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
企業コードSXTP
会社名60 Degrees Pharmaceuticals Inc
上場日Jul 12, 2023
最高経営責任者「CEO」Dr. Ll S. Dow, Ph.D.
従業員数3
証券種類Ordinary Share
決算期末Jul 12
本社所在地1025 Connecticut Avenue Nw
都市WASHINGTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号20036
電話番号12023275422
ウェブサイトhttps://60degreespharma.com/
企業コードSXTP
上場日Jul 12, 2023
最高経営責任者「CEO」Dr. Ll S. Dow, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし